What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2023-05-02 compared with 2022-11-08 · 134 added, 221 removed, 150 unchanged (70% of the section changed)

3 unchanged sentences

All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including without limitation statements regarding:

our financial performance, including our expectations regarding our existing cash, operating losses, expenses and sources of future financing;

the marketing and commercialization of IMCIVREE (setmelanotide), and the timing of commercialization;

the success, cost and timing of our product development activities and clinical trials;

our financial performance, including our expectations regarding

our existing cash, operating losses, expenses and sources of future financing;

our ability to hire and retain necessary personnel;

5 unchanged sentences

expectations surrounding our manufacturing arrangements;

the impact of the novel coronavirus, or COVID-19, pandemic on our business and operations and our future financial results;

the potential financial impact, growth prospects and benefits of our acquisition of Xinvento B.V.;

the impact of the novel coronavirus, or COVID-19, pandemic and the current economic slowdown on our business and operations and our future financial results;

and other statements identified by words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “likely,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms are forward-looking statements.

3 unchanged sentences

We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made .

We are a global, a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin 4 receptor (MC4R) pathway diseases.

Rhythm’s precision medicine, IMCIVREE ® (or setmelanotide), for which we have exclusive worldwide rights, has the potential to restore dysfunctional MC4R pathway signaling and MC4R pathway function.

MC4R pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity.

IMCIVREE is the first-ever therapy developed for patients with hyperphagia and severe obesity caused by certain rare MC4R pathway diseases that is approved or authorized in the United States, European Union (EU) or Great Britain.

In the United States, IMCIVREE is approved for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by a U.S.

Food and Drug Administration (FDA)-approved test demonstrating variants in POMC , PCSK1 or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance, or Bardet-Biedl syndrome (BBS).

The European Commission (EC) has authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above.

The UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above.

We have achieved market access for IMCIVREE in France, Germany and Great Britain, and we expect to secure market access in Italy and the Netherlands in the fourth quarter of 2022.

In addition to United States, EU and UK, we and our partners are seeking approval and market access for IMCIVREE to treat patients with these MC4R pathway-related obesities in Argentina and Israel.

We also are advancing a broad clinical development program evaluating setmelanotide in several ongoing clinical trials, and we are leveraging what we believe is the largest known DNA database focused on obesity - with approximately 45,000 sequencing samples as of December 31, 2021 - to improve the understanding, diagnosis and care of people living with severe obesity due to certain variants in genes associated with the MC4R pathway.

In April 2022, we enrolled the first patient in the pivotal Phase 3 EMANATE clinical trial, a randomized, double-blind, placebo-controlled trial to evaluate setmelanotide in four independent sub-studies in patients with obesity due to a heterozygous variant of the POMC/PCSK1 genes or LEPR gene or certain rare variants of the SRC1 gene or the SH2B1 gene.

We also have initiated the Phase 2 DAYBREAK clinical trial designed to evaluate setmelanotide in patients who carry a confirmed variant in one or more of 10 additional genes with strong or very strong relevance to the MC4R pathway.

In November 2022, we announced plans to initiate a pivotal, Phase 3 trial to evaluate setmelanotide in patients with hypothalamic obesity in early 2023.

In addition, our broad clinical programs evaluating setmelanotide in rare MC4R pathway diseases include the ongoing Phase 3 study in pediatric patients with MC4R pathway deficiencies between the ages of 2 and 6 years old, and a potential registration-enabling study with our once-weekly formulation of setmelanotide.

Additionally, as an FDA post-marketing requirement, we are currently evaluating the effects of setmelanotide on the QT interval corrected for heart rate, or QTc interval, in healthy volunteers.

There are currently no effective or approved treatments for these MC4R pathway related diseases.

We are a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients and their families living with rare diseases.

We are focused on advancing our lead asset, IMCIVREE ® (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases.

While obesity affects hundreds of millions of people worldwide, we are advancing IMCIVREE for a subset of individuals who have hyperphagia, a pathological hunger, and severe obesity due to an impaired MC4R pathway, which may be caused by traumatic injury or genetic variants.

The MC4R pathway is an endocrine pathway in the brain that is responsible for regulating hunger, caloric intake and energy expenditure, which consequently affect body weight.

IMCIVREE, an MC4R agonist for which we hold worldwide rights, is the first-ever therapy developed for patients with certain ultra-rare diseases that is approved or authorized in the United States, European Union (EU) and Great Britain.

IMCIVREE is approved by the U.S.

Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to:

(i) proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS);

or (ii) Bardet-Biedl syndrome (BBS).

The European Commission (EC) and Great Britain’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized IMCIVREE for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above.

We have achieved market access for IMCIVREE for BBS or POMC and LEPR deficiencies, or both, in nine countries including the United States, and we continue to collaborate with authorities to achieve and or expand access in additional markets.

In addition to initial commercial efforts, we are advancing what we believe is the most comprehensive clinical research program ever initiated in MC4R pathway diseases, with multiple ongoing and planned Phase 2 and Phase 3 clinical trials evaluating setmelanotide.

We are developing setmelanotide to address additional patients with acquired hypothalamic obesity.

In our Phase 2 trial evaluating setmelanotide as a treatment for hypothalamic obesity, as announced in November 2022, 16 of 18 patients achieved the primary endpoint with a body mass index (BMI) decrease greater than 5 percent on setmelanotide therapy, and we observed a 14.5 mean percent reduction in BMI across all patients.

On May 2, 2023, we announced that the first patients were dosed in our pivotal Phase 3 trial evaluating setmelanotide in patients with acquired hypothalamic obesity.

The Phase 3 clinical trial is designed to enroll 120 patients aged 4 years or older randomized 2:1 to setmelanotide therapy or placebo for a total of 60 weeks, including up to eight weeks for dose titration.

The primary endpoint is the percent change in BMI after approximately 52 weeks on a therapeutic regimen of setmelanotide versus placebo.

Key secondary

endpoints include the proportion of patients who achieve ≥5% reduction in BMI from baseline in adults (≥18) or BMI Z-score reduction of ≥0.2 from baseline in pediatrics after approximately 52 weeks on a therapeutic regimen of compared with placebo, and mean change in the weekly average of the daily most hunger score in patients ≥12 years from baseline after approximately 52 weeks on a therapeutic regimen of setmelanotide versus placebo.

We anticipate completing enrollment in this trial in the first quarter of 2024.

In addition, our ongoing pivotal Phase 3 EMANATE and Phase 2 DAYBREAK trials are designed to evaluate setmelanotide in several distinct, genetically defined MC4R pathway diseases.

We also are conducting a Phase 3 pediatrics trial evaluating daily setmelanotide in patients between the ages of two and six and a Phase 3 switch trial evaluating a weekly formulation of setmelanotide.

We are leveraging what we believe is the largest known DNA database focused on obesity - with approximately 60,000 sequencing samples as of December 31, 2022 - to improve the understanding, diagnosis and care of people living with severe obesity due to certain variants in genes associated with the MC4R pathway.

Our sequencing-based epidemiology estimates show that each of these genetically defined MC4R pathway deficiencies number in the rare or ultra-rare category, according to established definitions of rare disease patient populations.

Our epidemiology estimates are approximately 4,600 to 7,500 for U.S.

patients in initial FDA-approved indications, including obesity due to biallelic POMC, PCSK1 or LEPR deficiencies, and BBS.

Epidemiology estimates for patients with hypothalamic obesity is between 5,000 and 10,000 in the United States, based on our analysis of published literature and our epidemiology estimates for the indications being studied in our Phase 3 EMANATE trial suggest that approximately 53,000 U.S.

patients with one of these genetically driven obesities have the potential to respond well to setmelanotide.

There are currently no effective or approved treatments for these rare MC4R pathway related diseases.

The FDA has acknowledged the importance of these results by giving setmelanotide Breakthrough Therapy designation for the treatment of obesity associated with genetic defects upstream of the MC4R in the leptin melanocortin pathways.

1 unchanged sentence

Additional recent clinical, regulatory and commercial updates include:

On November 8, 2022, we announced that, as of September 30, 2022, more than 80 physicians have written more than 120 prescriptions for IMCIVREE for patients with BBS since IMCIVREE was approved by the FDA.

We have secured approval for reimbursement for more than 40 of those prescriptions.

On November 2, 2022, we also announced the design of our Phase 3 clinical trial in acquired hypothalamic obesity following recent discussions with the FDA.

The trial, which is anticipated to initiate in early 2023, is expected to enroll

120 patients randomized 2:1 to setmelanotide therapy or placebo for 60 weeks, including up to 8 weeks for dose titration.

The primary endpoint will be the percent change in body mass index (BMI) versus placebo.

Key secondary endpoints will include the proportion of patients who achieve ≥5% reduction in BMI from baseline in adults (≥18) or BMI Z-score reduction of ≥0.2 from baseline in pediatrics at Week 60 compared with placebo;

and mean change in the weekly average of the daily most hunger score in patients ≥12 years from baseline to Week 60 compared with placebo.

At The Obesity Society’s ObesityWeek ® 2022 conference held November 1-4, 2022 in San Diego, California, we and our collaborators delivered 11 presentations.

Highlights from the presentations include:

● Positive full dataset from our Phase 2 trial evaluating setmelanotide for the treatment of hypothalamic obesity demonstrating that 89% percent (16 of 18) patients had a 5% or greater reduction in BMI at 16 weeks;

14.5 mean percent reduction in BMI and 12.6 mean percent reduction body weight (N=18) at Week 16 from baseline;

● Additionally, we reported that 14 patients continued on therapy in our long-term extension trial.

As of a cut-off date of September 23, 2022, 13 of these patients who reached a total of 29 weeks on setmelanotide therapy achieved a mean BMI reduction of 21.1% (SD, 11.2%);

and five (5) of these patients who reached a total of 41 weeks on setmelanotide therapy achieved a mean BMI reduction of 26.7% (SD, 12.4%).

● Results from the Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS):

We also presented results from CRIBBS, the international registry of patients with BBS that launched in 2014.

We collaborated with the Marshfield Clinic Research Institute on multiple analyses of blinded CRIBBS data.

The results demonstrated that children with BBS experience high disease burden due to hyperphagia and that hyperphagia was positively correlated with higher BMI weight categories.

Obesity was found to be highly prevalent in a large sample of children with BBS, and most children who had obesity continued to have it or experienced worsening weight gain over time.

On November 1, 2022, we also announced that the FDA has granted Breakthrough Therapy designation to setmelanotide for the treatment of hypothalamic obesity.

The FDA's Breakthrough Therapy designation is designed to expedite development and review of medicines that aim to address a serious condition with preliminary clinical evidence indicating that the drug may demonstrate substantial improvement over existing treatments on one or more clinically significant endpoints.

On October 12, 2022, we announced our sponsorship of the inaugural International Meeting on Pathway-Related Obesity:

Vision of Excellence (IMPROVE) 2022 in Berlin, Germany, bringing together approximately 100 specialists to share the latest scientific developments and patient care practices related to rare MC4R pathway-related obesities.

Also on October 12, 2022 at IMPROVE, we announced data from our exploratory Phase 2 Basket Study evaluating setmelanotide in patients stratified into two cohorts, one with predicted setmelanotide rescuable MC4R pathway deficiency and one with predicted nonrescuable MC4R deficiency.

On October 6, 2022, we announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of our Executive Leadership Team to lead our robust clinical development program, clinical operations, and data management.

On September 23, 2022, we announced the publication of a children’s book developed in collaboration with the BBS Foundation entitled, “Understanding Hunger & Bardet-Biedl Syndrome (BBS):

Gabe’s Story.”

On September 19, 2022, we completed a public offering of 4,800,000 shares of common stock at a price to the public of $26.00 per share for aggregate net proceeds to us of $117.0 million, after deducting underwriting discounts and commissions and offering expenses payable by us.

On October 18, 2022, we completed the sale of an additional 580,000 shares of common stock at a price to the public of $26.00 per share pursuant to the partial exercise of the underwriters’

option to purchase additional shares, for aggregate net proceeds to us of approximately $131.2 million, after deducting underwriting discounts, commissions and offering expenses payable by us.

On September 19, 2022, we announced presentations during the 60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE 2022) held in Rome, Italy that detailed new findings on the burden of hyperphagia and obesity on patients with BBS and their caregivers and data from new analyses that showed setmelanotide achieved substantial weight loss benefit in adolescent and pediatric patients with rare MC4R pathway diseases across three separate pivotal trials.

On September 6, 2022, we announced that the EC has expanded the marketing authorization for IMCIVREE to include the treatment of obesity and control of hunger associated with genetically confirmed BBS in adult and pediatric patients 6 years of age and older.

Also on September 6, 2022, we announced that Health Canada granted Priority Review for our New Drug Submission (NDS) for setmelanotide, indicated in adult and pediatric patients 6 years of age and older with impairments in the MC4R pathway due to genetic diseases, for the treatment of obesity and control of hunger in BBS or biallelic POMC, PCSK1, LEPR deficiency.

Priority Review shortens Health Canada’s submission review performance target to 180 days, in comparison to 300 days for non-Priority Review.

In addition, we reported that we expect to achieve the following near-term milestones:

● Launch IMCIVREE in Italy and the Netherlands for patients with POMC, PCSK1 or LEPR deficiencies in the fourth quarter of 2022;

● Initiate pivotal Phase 3 trial to evaluate setmelanotide in hypothalamic obesity in early 2023;

● Initiate a Phase 3, randomized, double-blind trial in patients naïve to setmelanotide therapy (“de novo study”) to evaluate the weekly formulation of setmelanotide in patients with BBS in the first half of 2023;

● Complete regulatory review by Health Canada and, pending approval, make IMCIVREE commercially available in Canada for the treatment of obesity and control of hunger in adults and pediatric patients 6 years and older with BBS, or with POMC, PCSK1 or LEPR deficiencies in 2023;

● Announce topline data from our Phase 3, open-label trial evaluating one year of setmelanotide therapy in pediatric patients with MC4R pathway deficiencies between the ages of 2 and 6 years old in the second half of 2023.

On February 27, 2023, we completed the acquisition of Xinvento B.V.

(Xinvento), a Netherlands-based biotech company focused on developing therapies for congenital hyperinsulinism (CHI).

At closing, Rhythm BV, pursuant to a Share Purchase Agreement, or the Purchase Agreement, with Xinvento, acquired all of the issued and outstanding shares of Xinvento for aggregate consideration of $5 million, as adjusted pursuant to the terms of the Purchase Agreement and subject to the distribution and payment terms set forth therein.

In addition, the Purchase Agreement provides for the payment of additional consideration totaling up to $206.0 million upon achievement of certain development, regulatory and commercial milestones by Xinvento.

CHI is a rare genetic disease in which cells secrete excess insulin, causing hypoglycemia, which can result in serious health outcomes including seizures, coma, permanent brain damage and death.

We plan to expand our pipeline into CHI, a rare disease that is well aligned with our corporate strategy and our focus on rare endocrinology indications.

On May 2, 2023, we announced that we had received more than 300 new prescriptions for IMCIVREE for BBS from more than 175 physicians in the United States with reimbursement approvals for more than 160 of those prescriptions from FDA approval between June 16, 2022 to March 31, 2023.

More than 100 of the total new prescriptions were written in the first quarter of 2023.

On April 24, 2023, we also announced the commercial launch of IMCIVREE in Germany for the treatment of obesity and control of hunger associated with BBS with federal reimbursement.

The German Federal Joint Committee (G-BA) previously ruled that IMCIVREE is eligible for reimbursement by Statutory Health Insurances for BBS based on its unanimous vote to exclude IMCIVREE from its lifestyle exemption list for patients with BBS.

On March 27, 2023, we announced the publication of research in the peer-reviewed journal Advances in Therapy that demonstrated setmelanotide improved hyperphagia and reduced obsessive focus on food and body weight in patients

with BBS and the publication of an assessment of the substantial impact of severe hyperphagia on patients’ quality of life in the open-access journal Obesity Science and Practice .

We also expect to achieve the following near-term milestones:

● Present data analyses from the Phase 2 and long-term extension trials in hypothalamic obesity in the fall of 2023;

● Complete regulatory review by Health Canada and, pending approval, make IMCIVREE commercially available in Canada for the treatment of BBS, or POMC, PCSK1 or LEPR deficiencies in the second half of 2023;

● Announce preliminary data from the open-label part of the Phase 2 DAYBREAK trial from one or more genetically defined cohorts in the second half of 2023;

● Announce topline data from the ongoing Phase 3, open-label pediatrics trial evaluating one year of setmelanotide therapy in patients with MC4R pathway deficiencies between the ages of two and six years old in the second half of 2023;

● Announce topline data from the ongoing Phase 3 switch trial evaluating a weekly formulation of setmelanotide in the second half of 2023;

● Provide an update on early-stage R&D efforts in the fourth quarter of 2023, including details of the CHI pre-clinical development program and IND expected in 2024.

Our operations to date have been limited primarily to conducting research and development activities for setmelanotide.

To date, we have generated less than $15.0 million of revenue from product sales and we have financed our operations primarily through the proceeds received from the sales of common and preferred stock, asset sales, as well as capital contributions from the former parent company, Rhythm Holdings LLC.

To date, we have not generated sufficient cash flows from product sales and we have financed our operations primarily through the proceeds received from the sales of common and preferred stock, royalty interest financing, asset sales, collaboration and license agreements, as well as capital contributions from the former parent company, Rhythm Holdings LLC.

From August 2015 through August 2017, we raised aggregate net proceeds of $80.8 million through our issuance of series A preferred stock.

Since our initial public offering, or IPO, on October 10, 2017 and our underwritten follow-on offerings through October 2022, we have raised aggregate net proceeds of approximately $742.6 million through the issuance of our common stock after deducting underwriting discounts, commissions and offering related transaction costs.

We also received $100.0 million from an asset sale, specifically in connection with the sale of our PRV.

In December 2021, we entered into an Exclusive License Agreement with RareStone Group Ltd., and received $7.0 million in connection with the execution of that agreement.

In June 2022, we entered into the RIFA (as defined below) with entities managed by HealthCare Royalty and received cumulative proceeds of $74.8 million, net of certain transaction costs at closing.

We will not generate significant revenue from product sales until we are able to successfully establish a marketing and commercialization infrastructure for IMCIVREE.

IMCIVREE became commercially available to patients 6 years of

age and older with obesity due to POMC, PCSK1 or LEPR deficiency in the U.S.

We also received $100.0 million from an asset sale, specifically in connection with the sale of our Rare Pediatric Disease Priority Review Voucher, or PRV, to Alexion Pharmaceuticals, Inc.

in February 2021.

In December 2021, we entered into an Exclusive License Agreement with RareStone Group Ltd.

, and received $7.0 million in connection with the execution of that agreement.

In June 2022, we entered into the Revenue Interest Financing Agreement, or RIFA, with entities managed by HealthCare Royalty Partners, LLC, or HealthCare Royalty, and received cumulative proceeds of $73.2 million, net of certain transaction costs at closing.

Additionally, there is $25.0 million of additional proceeds available to us under our RIFA if certain sales-based milestones are achieved during 2023.

IMCIVREE became commercially available to patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency in the U.S.

in the first quarter of 2021 and patients 6 years of age and older with obesity due to BBS during June 2022.

2 unchanged sentences

We expect to continue to fund our operations through the sale of equity, debt financings or other sources.

We intend to build our own marketing and commercial sales infrastructure and we may enter into collaborations with other parties for certain markets outside the United States.

We have built our own marketing and commercial sales infrastructure in the United States

and are in the process of building a similar infrastructure in several European markets and the United Kingdom.

We may enter into collaborations with other parties for certain markets outside the United States.

However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms, or at all.

If we fail to raise capital or enter into such other arrangements as, and when, needed, we may have to significantly delay, scale back or discontinue the development or commercialization of setmelanotide.

As of September 30, 2022, we had an accumulated deficit of $667.6 million.

Our net losses were $40.9 million, $35.1 million, $138.6 million, and $26.7 million for the three and nine months ended September 30, 2022 and 2021, respectively.

As of March 31, 2023 we had an accumulated deficit of $762.2 million.

Our net losses were $52.2 million and $52.8 million, for the three months ended March 31, 2023 and 2022, respectively.

We expect to continue to incur significant expenses and increasing operating losses over the foreseeable future.

7 unchanged sentences

● continue to operate as a public company.

As of September 30, 2022, our existing cash and cash equivalents and short-term investments were approximately $347.8 million.

We expect that our previously announced changes to the EMANATE and DAYBREAK trials, coupled with a streamlining of our planned global network of clinical trial sites, will result in meaningful cost savings.

As of March 31, 2023, our existing cash and cash equivalents and short-term investments were approximately $294.6 million.

We expect that our existing cash and cash equivalents and short-term investments will be sufficient to fund our operations into 2025.

1 unchanged sentence

We are a Delaware corporation organized in February 2013 under the name Rhythm Metabolic, Inc., and as of October 2015, under the name Rhythm Pharmaceuticals, Inc.

Impact of COVID-19

We are closely monitoring how the continued spread of COVID-19 is affecting our employees, business, preclinical studies and clinical trials.

In response to the COVID-19 pandemic, we have limited access to our executive offices with most employees continuing their work outside of our offices and travel has been restricted.

Based on current information we do not currently anticipate any disruption in the clinical supply of setmelanotide.

Our CMOs have indicated that they have appropriate plans and procedures in place to ensure uninterrupted future supply of clinical and commercial-grade setmelanotide, subject to potential limitations on their operations due to COVID-19.

As a result, we do not currently expect that the COVID-19 pandemic will have a material impact on our business, results of operations and financial condition.

At this time, however, there is still uncertainty relating to the trajectory of the pandemic and the impact of

related responses, and disruptions caused by the COVID-19 pandemic have resulted and may in the future result in difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials and the incurrence of unforeseen costs as a result of disruptions in clinical supply or preclinical study or clinical trial delays.

For example, in 2020, we experienced interruption of key clinical trial activities, such as patient attendance and clinical trial site monitoring, in our Phase 3 clinical trial evaluating setmelanotide for the treatment of insatiable hunger and severe obesity in individuals with BBS or Alström syndrome.

The impact of COVID-19 on our future results will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, the impact of variants, evolving travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, the ultimate impact on financial markets and the global economy, the effectiveness of vaccines and vaccine distribution efforts and the effectiveness of other actions taken in the United States and other countries to contain and treat the disease.

See “Risk Factors—The COVID-19 pandemic has and may continue to adversely impact our business, including our preclinical studies, clinical trials and our commercialization prospects.” in Part II, Item 1A of this Quarterly Report on Form 10-Q.

Financial Operations Overview

3 unchanged sentences

We recorded our first sales of IMCIVREE in the United States in March 2021 and we made our first sales in France during March 2022 under the paid early access program.

IMCIVREE was approval by the FDA and the EC in adult and pediatric patients six years of age and older with obesity due to BBS in June and September of 2022, respectively.

IMCIVREE was approval by the FDA and the EC in adult and pediatric patients six years of age and older with obesity due to BBS in June and September 2022, respectively.

Following these approvals for BBS, we expect our sales of IMCIVREE will continue to grow as we identify and treat more patients with this disease and obtain reimbursement throughout the international markets in which we operate.

2 unchanged sentences

Most of the manufacturing costs have been recorded as research and development expenses in prior periods.

Accordingly, the costs for IMCIVREE included in our cost of sales for the three and nine months ended September 30, 2022 were insignificant.

We expect cost of sales to increase in 2022 as we continue to sell inventory that is produced after we began capitalizing IMCIVREE commercial inventory.

We continue to evaluate the impact of this previously expensed inventory on the future cost of product sales, however we do not expect there to be a significant impact based on the cost structure of the product.

Accordingly, the product cost component related to IMCIVREE included in cost of sales for the three months ended March 31, 2023 and 2022 was insignificant.

We expect cost of sales to increase in 2023 as we continue to sell inventory that is produced after we began capitalizing manufacturing costs for IMCIVREE commercial inventory.

We do not expect there to be a significant impact to our cost of sales based on the cost structure of the product.

Research and development expenses

10 unchanged sentences

Three Months Ended

Nine Months Ended

September 30,

Research and development summary

15 unchanged sentences

Selling expenses consist of professional fees related to preparation for the commercialization of setmelanotide, as well as salaries and related benefits for commercial employees, including stock-based compensation.

As we implement and execute our commercialization plans and start to market setmelanotide and as we explore new collaborations to develop and commercialize setmelanotide, we anticipate that these expenses will materially increase.

As we further implement and execute our commercialization plans to market setmelanotide in new territories and as we explore new collaborations to develop and commercialize setmelanotide, we anticipate that these expenses will materially increase.

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, relating to our full-time employees not involved in R&D or commercial activities.

2 unchanged sentences

Three Months Ended

Nine Months Ended

September 30,

Selling, general and administrative summary

Selling, general and administrative expense

We anticipate that our selling, general and administrative expenses will increase in the future to support continued and expanding development efforts, commercialization of IMCIVREE in the United States and the European Union as well as increased costs of operating as a global commercial stage biopharmaceutical public company.

We anticipate that our selling, general and administrative expenses will increase in the future to support continued and expanding commercialization efforts for IMCIVREE in the United States and the European Union as well as increased costs of operating as a global commercial stage biopharmaceutical public company.

These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, compliance with local rules and regulations in the United States and foreign jurisdictions, exchange listing and Securities and Exchange Commission (SEC) expenses, insurance and investor relations costs, among other expenses.

7 unchanged sentences

Results of Operations

Comparison of the three months ended September 30, 2022 and 2021

The following table summarizes our results of operations for the three months ended September 30, 2022 and 2021, together with the changes in those items in dollars and as a percentage:

Comparison of the three months ended March 31, 2023 and 2022

The following table summarizes our results of operations for the three months ended March 31, 2023 and 2022, together with the changes in those items in dollars and as a percentage:

Three Months Ended

September 30,

(in thousands)

7 unchanged sentences

Loss from operations

Other (expense) income, net

Loss before taxes

Benefit from income taxes

NM=Not meaningful

Other income (expense), net

Product revenue, net .

Product revenue, net increased by $3.3 million to $4.3 million for the three months ended September 30, 2022 from $1.0 million for the three months ended September 30, 2021, an increase of 317%.

The FDA approved our lead product candidate, IMCIVREE in November 2020 and we recorded our first sales of IMCIVREE in March 2021.

We expect our sales of IMCIVREE to continue to increase following the FDA approval for the treatment of patients with BBS in the United States during June 2022 and by the EC in September 2022.

Through September 30, 2022, a substantial amount of our product revenue, or 81%, has been generated in the United States.

During March 2022, we completed our first sales of IMCIVREE in France through an early access program.

During June 2022, we completed our first sales of IMCIVREE in Germany.

Product revenue, net increased by $10.0 million to $11.5 million for the three months ended March 31, 2023 from $1.5 million for the three months ended March 31, 2022, an increase of 666%.

During the three months ended March 31, 2023 and 2022, a substantial amount of our product revenue, or 83% and 98%, respectively, has been generated in the United States.

Cost of sales.

Cost of sales increased by $0.3 million to $0.5 million for the three months ended September 30, 2022 from $0.2 million for the three month period ended September 30, 2021.

All of our inventory of IMCIVREE produced prior to FDA approval is available for commercial or clinical use.

Most of the manufacturing costs have been recorded as research and development expenses in prior periods.

Accordingly, the costs for IMCIVREE included in our cost of sales for the three months ended September 30, 2022 and 2021 were insignificant and primarily reflect the amortization of our capitalized sales based milestone payment made to Ipsen Pharma S.A.S., or Ipsen, upon our first commercial sale in the United States and European Union, as well as a royalty due to Ipsen on our net product sales.

Cost of sales increased by $1.2 million to $1.4 million for the three months ended March 31, 2023, an increase of 518%.

Most of the IMCIVREE manufacturing costs have been recorded as research and development expenses in prior periods.

Accordingly, the product cost component related to IMCIVREE included in our cost of sales for the three months ended March 31, 2023 and 2022 was insignificant.

Cost of sales primarily reflects a royalty due to Ipsen Pharma S.A.S., or Ipsen, on our net product sales and the amortization of our capitalized sales-based milestone payment made to Ipsen, upon our first commercial sale in the U.S.

Specifically, the $1.2 million increase in cost of sales for the three months ended March 31, 2023 was due to $0.5 million of additional royalties due to our growth in sales, $0.6 million attributed to product cost primarily associated with higher sales volume and product distributed for our patient assistance program, and $0.1 million of additional amortization.

We expect cost of sales to increase over time as we sell inventory that is produced after we began capitalizing IMCIVREE commercial inventory.

Research and development expense.

Research and development expense decreased by $6.4 million to $21.1 million in 2022 from $27.5 million in 2021, a decrease of 23%.

The decrease was primarily due to the following:

● a decrease of $5.2 million in our clinical trial costs associated with the impact of study design amendments to our Phase 2 DAYBREAK study, as well as, reduced activity due to the winding down of our BBS, QT, Phase 2 Basket and renal studies;

these decreases were partially offset by increased costs associated with our Phase 3 EMANATE trials, and increased enrollment in our long-term extension study;

● a decrease of $1.3 million in costs associated with the manufacturing of clinical material;

● a decrease of $0.5 million of costs related to next generation research and development activities;

● a decrease of $0.4 million in costs associated with medical affairs;

● a decrease of $0.3 million in compensation and benefits.

The above decreases were partially offset by:

Research and development expense increased by $5.4 million to $37.9 million in 2023 from $32.5 million in 2022, an increase of 17%.

The net increase was primarily due to the following:

● the purchase of in-process research and development assets of $5.4 million from Xinvento;

● an increase of $2.6 million in salaries, benefits and stock-based compensation related to the hiring of additional full-time employees in order to support the growth of our research and development programs;

● an increase of $1.7 million due to increased gene sequencing costs to support our expanded clinical programs.

Selling, general and administrative expense.

Selling, general and administrative expense increased by $4.4 million to $21.9 million in 2022 from $17.5 million in 2021, an increase of 25%.

The increase was primarily due to the following:

● an increase of $2.2 million due to increased compensation and benefits related costs associated with additional headcount to support our expanding business operations as well as to build out our commercial operations in the United States and internationally ;

● an increase of $1.6 million due to increased costs associated with insurance premiums, office support, travel and entertainment related costs for our expanding workforce and increased commercial operations;

● an increase of $0.7 million related to increased costs associated with sales and marketing activities for IMCIVREE in connection with preparing for the EC approval for BBS obtained in September 2022 and expanding our international market access.

The above increases were partially offset by:

● a decrease of $0.4 million related to professional services costs.

Other (expense) income, net.

Other (expense) income, net decreased by $1.7 million to ($1.6) million for the three months ended September 30, 2022.

Other (expense) income, net consists of ($2.1) million of interest expense related to our RIFA with HealthCare Royalty Partners, LLC and a ($1.0) million write off expense related to our RareStone equity partially offset by $1.0 million of interest income primarily due to improving interest rates during the period and $0.7 million fair market value adjustment related to our RIFA embedded derivative.

(Benefit from) provision for income taxes.

There is no provision for income taxes for the three months ended September 30, 2022, as we project to generate operating losses during the year.

We recorded an income tax benefit of $9.0 million as a result of the reversal of a tax provision recorded upon the sale of our PRV during the three months ended September 30, 2021.

Net loss increased by $5.8 million to $40.9 million for the three months ended September 30, 2022, from net loss of $35.1 million for the three months ended September 30, 2021.

The increase in net loss was a result of higher costs as noted above, offset by current period revenues, and the non-recurring nature of the impact of a tax benefit related to the sale of our PRV in the prior year period.

Comparison of the nine months ended September 30, 2022 and 2021

The following table summarizes our results of operations for the nine months ended September 30, 2022 and 2021, together with the changes in those items in dollars and as a percentage:

Nine Months Ended

September 30,

(in thousands)

Statement of Operations Data:

Product Revenue, net

License revenue

Costs and expenses:

Cost of sales

Research and development

Selling, general, and administrative

Total costs and expenses

Loss from operations

Other (expense) income, net

Loss before taxes

Provision for income taxes

NM=Not meaningful

Product revenue, net.

Product revenue, net increased by $6.8 million to $8.1 million for the nine months ended September 30, 2022 from $1.3 million for the nine months ended September 30, 2021, an increase of 505%.

The FDA approved our lead product candidate, IMCIVREE in November 2020 and we recorded our first sales of IMCIVREE in March 2021.

We expect our sales of IMCIVREE to continue to increase following the FDA approval for the treatment of

patients with BBS in the United States during June 2022 and by the EC during September 2022.

Through September 30, 2022, substantially all of our product revenue, or 86%, has been generated in the United States.

During March 2022, we completed our first sales of IMCIVREE in France through an early access program.

During June 2022, we completed our first sales of IMCIVREE in Germany.

License revenue.

License revenue was $6.8 million for the nine months ended September 30, 2022 and was entirely related to the RareStone license.

We entered into a license agreement with the RareStone in December 2021 and completed our activities required to transfer the license to RareStone during the second quarter of 2022, which resulted in the recognition of the license revenue.

We do not expect to recognize additional license revenue related to the RareStone arrangement during 2022.

Cost of sales.

Cost of sales increased by $0.7 million to $1.1 million for the nine months ended September 30, 2022 from $0.4 million in the nine months ended September 30, 2021, an increase of 204%.

Most of the IMCIVREE manufacturing costs have been recorded as research and development expenses in prior periods.

Accordingly, the product cost component related for IMCIVREE included in our cost of sales for the nine months ended September 30, 2022 were insignificant and cost of sales primarily reflect the amortization of our capitalized sales based milestone payment made to Ipsen Pharma S.A.S., or Ipsen, upon our first commercial sale in the United States and European Union, as well as a royalty due to Ipsen on our net product sales.

The $0.7 million increase in cost of sales was due to an increase of $0.3 million of additional amortization, $0.3 million of additional royalties due to our growth in sales and $0.1 attributed to product cost primarily associated with higher sales volume.

We expect cost of sales to increase overtime as we sell inventory that is produced after we began capitalizing IMCIVREE commercial inventory.

Research and development expense.

Research and development expense increased by $12.5 million to $85.1 million in the nine months ended September 30, 2022 from $72.6 million in the nine months ended September 30, 2021, an increase of 17%.

The increase was primarily due to the following:

● an increase of $8.8 million in our clinical trial costs associated with new and planned clinical trials, including our Phase 2 DAYBREAK and Phase 3 EMANATE trials, Phase 3 pediatrics trial, QTc study, Phase 2 hypothalamic obesity study, and increased enrollment in our long-term extension study.

These increases were partially offset by reduced activity due to the completion and winding down of our POMC LEPR, BBS, Phase 2 Basket, renal and GO-ID studies;

● an increase of $3.0 million due to increased purchases of clinical supply material;

● an increase of $2.4 million due to increased gene sequencing costs associated with our expanded clinical programs;

● an increase of $1.1 million in compensation and benefits due to the hiring of additional full-time employees in order to support the growth of our research and development programs and expansion of regulatory affairs operations;

● an increase of $1.0 million in development milestones earned by Camurus AB, or Camurus, related to development milestone achieved related to our weekly formulation;

● an increase of $0.3 million related to IP and patent related filing activities.

The above increases were partially offset by:

● a decrease of $3.7 million in costs associated with medical affairs;

● a decrease of $0.7 million in costs associated with next generation research and development activities.

● a decrease of $2.8 million in our clinical trial costs associated with the impact of study design amendments to our reduced activity due to the completion and winding down of our Phase 2 hypothalamic obesity study, Phase 2 DAYBREAK, QTc trial, BBS trial, Phase 2 Basket trial, Phase 3 pediatrics trial and our renal study, long-term extension and switch trials.

These decreases were partially offset by increased activity in our Phase 3 EMANATE trials, and Phase 3 hypothalamic obesity study;

● a decrease of $0.7 million in costs associated with the manufacturing of clinical material;

● a decrease of $1.0 million in development milestones earned by Camurus AB, or Camurus related to development milestone achieved related to our weekly formulation.

Selling, general and administrative expense.

Selling, general and administrative expense increased by $18.2 million to $65.7 million in the nine months ended September 30, 2022 from $47.5 million in the nine months ended September 30, 2021, an increase of 38%.

Selling, general and administrative expense increased by $3.2 million to $24.6 million in 2023 from $21.4 million in 2022, an increase of 15%.

The increase was primarily due to the following:

● an increase of $8.1 million related to increased costs associated with commercial operations, sales and marketing activities for IMCIVREE in connection with preparing for the U.S.

approval for BBS obtained in June 2022 and EC approval in September 2022;

● an increase of $2.6 million due to increased compensation and benefits related costs associated with additional headcount to support our expanding business operations as well as to build out our commercial operations in the United States and internationally ;

● an increase of $1.0 million related to professional services costs;

● an increase of $0.9 million due to increased costs associated with information technology, international office space, sponsorships and general corporate travel related expenses for our expanding workforce

Other (expense) income, net.

Other (expense) income, net decreased by $101.9 million to ($1.6) million in the nine months ended September 30, 2022.

The decrease was primarily due to the sale of our PRV in February 2021.

The sale of our PRV in the prior year was a non-recurring transaction.

Other (expense) income, net consists of $2.2 million of interest expense related to our RIFA and a $1.0 million write-off expense related to our RareStone equity for the nine months ended September 30, 2022, partially offset by $1.4 million of interest income and $0.7 million of other income resulting from the remeasurement of our embedded derivative related to our RIFA.

Provision for income taxes.

There is no provision for income taxes for the nine months ended September 30, 2022, as we project to generate operating losses during the year.

We recorded a provision for income taxes of $8.0 million as a result of the sale of our PRV during the nine months ended September 30, 2021.

Net loss increased by $111.9 million to $138.6 million for the nine months ended September 30, 2022, from net loss of $26.7 million for the nine months ended September 30, 2021.

The increase in net loss was primarily a result of the non-recurring nature of our PRV sale in 2021, which resulted in $100.0 million of other income during the prior year period, as well as higher costs partially offset by product and license revenue in the current year as noted above.

The above increases were partially offset by:

● a decrease of $1.2 million related to costs associated with sales and marketing activities for IMCIVREE in preparation of BBS launch during the prior year.

Other income (expense), net.

Other income (expense), net increased by $0.4 million to $0.4 million for the three months ended March 31, 2023.

Total other income (expense), net for the three months ended March 31, 2023 consists of interest income of $3.4 million primarily due to improved interest rates, partially offset by $3.0 million of interest expense related to our RIFA with HealthCare Royalty and a $0.1 million fair market value adjustment related to our RIFA embedded derivative.

Net loss decreased by $0.6 million to $52.2 million for the three months ended March 31, 2023,

from net loss of $52.8 million for the three months ended March 31, 2022.

The decrease in net loss was a result of

higher product revenue, net and other income (expense), net, offset by higher current period costs and expenses, as noted above.

Liquidity and Capital Resources

As of September 30, 2022, our cash and cash equivalents and short-term investments were approximately $347.8 million.

The following table provides information regarding our cash flows for the nine months ended September 30, 2022 and 2021:

Nine Months Ended September 30,

As of March 31, 2023, our cash and cash equivalents and short-term investments were approximately $294.6 million.

The following table provides information regarding our cash flows for the three months ended March 31, 2023 and 2022:

Three Months Ended March 31,

(in thousands)

Net cash provided by (used in):

Net cash (used in) provided by:

Operating activities

1 unchanged sentence

Financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash

Effect of exchange rates on cash

Net (decrease) increase in cash, cash equivalents and restricted cash

Net cash used in operating activities

The use of cash in all periods resulted primarily from our net loss adjusted for non-cash charges and changes in components of working capital.

Net cash used in operating activities was $139.4 million for the nine months ended September 30, 2022 and consisted primarily of a net loss of $120.9 million adjusted for non-cash items, which consisted of non-cash stock-based compensation, depreciation and amortization and rent expense.

The change in operating assets and liabilities reflected a total use of cash of approximately $4.9 million from a decrease in other long-term assets, prepaid expenses and other current assets coupled with a $13.7 million decrease in accounts payable, deferred revenue and accrued expenses and other current liabilities.

Net cash used in operating activities was $105.5 million for the nine months ended September 30, 2021 and consisted primarily of a net loss of $102.0 million adjusted for non-cash items, which consisted of non-cash stock-based compensation, the gain on the sale of the PRV, a deferred provision for income taxes, depreciation and amortization and rent expense.

The change in operating assets and liabilities reflected a total use of cash of approximately $5.4 million from an increase in accounts payables and accrued expenses associated with our CROs, CMOs, and consultants due to the timing of payments, offset by an increase of $8.9 million in prepaid expenses.

Net cash provided by (used in) investing activities

Net cash provided by investing activities was $68.8 million for the nine months ended September 30, 2022 and relates to $224.6 million of maturities of short-term investments, partially offset by $151.5 million of purchases of short-term investments, a $4.0 million milestone obligation payment under our license agreement with Ipsen and $0.3 million related to the purchase of property plant and equipment.

Net cash used in investing activities was $69.4 for the nine months ended September 30, 2021 and relates to $164.0 million of net purchases of short-term investments, $0.4 million related to the purchase of property plant and equipment and $5.0 million for the acquisition of an intangible asset, partially offset by the $100.0 million in proceeds from the sale of the PRV.

Net cash provided by financing activities

Net cash provided by financing activities was $196.5 million for the nine months ended September 30, 2022, which represents the net proceeds of $117.0 million from our common stock offering in September 2022, net proceeds from of $75.0 million from the RIFA, and $4.5 million of cash proceeds from the exercise of stock options and the issuance of common stock from our 2017 Employee Stock Purchase Plan, or the ESPP.

Net cash provided by financing activities was $166.4 million for the nine months ended September 30, 2021, which represents the net proceeds of $161.7 million from our common stock offering in February 2021 and $4.7 million of cash proceeds from the exercise of stock options and the issuance of common stock from the ESPP.

Net cash used in operating activities was $36.4 million for the three months ended March 31, 2023 and consisted primarily of a net loss of $52.2 million adjusted for non-cash items of $9.9 million, which consisted of non-cash stock-based compensation, depreciation and amortization, rent expense and the change in the fair value of our embedded derivative liability.

Our net loss also includes $5.4 million of acquired IPR&D assets, which are classified as investing activities.

The change in operating assets and liabilities provided cash of approximately $0.4 million primarily driven by a net increase in accounts payable and accrued expenses of $5.2 million due to the timing of payments, offset by increases in accounts receivable and inventory of $4.5 million and a net increase in prepaid expenses and other assets of $0.3 million.

Net cash used in operating activities was $53.6 million for the three months ended March 31, 2022 and consisted primarily of a net loss of $52.8 million, adjusted for non-cash items of $4.9 million, which consisted of non-cash stock-based compensation, depreciation and amortization and rent expense.

The change in operating assets and liabilities reflected a total use of cash of approximately $5.8 million from an increase in other long-term assets of $6.7 million, offset by a decrease of $0.9 million in prepaid expenses.

Net cash provided by investing activities

Net cash provided by investing activities was $18.5 million for the three months ended March 31, 2023 and relates to $92.7 million of maturities of short-term investments, partially offset by $69.6 million of purchases of short-term investments.

We also used approximately $4.5 million to acquire Xinvento’s IPR&D assets and $0.1 million to the purchase of property plant and equipment.

Net cash provided by investing activities was $72.5 million for the three months ended March 31, 2022 and relates to the $112.1 million of maturities of short-term investments, offset by $39.5 million of purchases of short-term investments, and $0.1 million related to the purchase of property plant and equipment.

Net cash (used in) provided by financing activities

Net cash used in financing activities was $0.1 million for the three months ended March 31, 2023, which comprised of a $1.3 million RIFA payment partially offset by $1.2 million of cash proceeds from the exercise of stock options and the issuance of common stock from our 2017 Employee Stock Purchase Plan, or the ESPP.

Net cash provided by financing activities was $0.4 million for the three months ended March 31, 2022, which represents the net proceeds of the issuance of common stock from the ESPP.

Revenue Interest Financing Agreement

On June 16, 2022, we announced a non-dilutive revenue interest financing agreement, or RIFA, with HealthCare Royalty Partners, LLC, or HealthCare Royalty, for a total investment amount of up to $100 million.

On June 16, 2022, we announced a non-dilutive Revenue Interest Financing Agreement, or RIFA, with HealthCare Royalty, for a total investment amount of up to $100 million.

In exchange for the total investment amount to be received by Rhythm, HealthCare Royalty will receive a tiered royalty based on global net product sales generated by IMCIVREE.

5 unchanged sentences

We expect that our existing cash and cash equivalents and short-term investments will be sufficient to fund our operations into 2025.

Our cash and cash equivalents are maintained at financial institutions in amounts that exceed federally-insured limits.

In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we will be able to access uninsured funds in a timely manner or at all.

We may need to obtain substantial additional funding in connection with our research and development activities and any continuing operations thereafter.

5 unchanged sentences

● the obligations owed to Ipsen, Camurus and Takeda pursuant to our license agreements;

● the obligations owed to Xinvento pursuant to our purchase agreement

● the extent to which we acquire or in-license other product candidates and technologies;

6 unchanged sentences

Adequate additional financing may not be available to us on acceptable terms, or at all.

In addition, the magnitude and duration of the COVID-19 pandemic and its impact on our liquidity and future funding requirements is uncertain as of the filing date of this Quarterly Report as this continues to evolve globally.

In addition, the impact of the COVID-19 pandemic on our liquidity and future funding requirements is uncertain as of the filing date of this Quarterly Report as this continues to evolve.

See “Impact of COVID-19” above and “Risk Factors— The COVID-19 pandemic has and may continue to adversely impact our business, including our preclinical studies, clinical trials and our commercialization prospects.” in Part II, Item 1A of this Quarterly Report for a further discussion of the possible impact of the COVID-19 pandemic on our business.

Further, the global economy, including credit and financial markets, has recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, rising interest and inflation rates, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability.

All of these factors could impact our liquidity and future funding requirements, including but not limited to our ability to raise additional capital when needed on acceptable terms, if at all.

The duration of this economic slowdown is uncertain and the impact on our business is difficult to predict.

See “Risk Factors— Unfavorable global political or economic conditions could adversely affect our business, financial condition or results of operations.”

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements.

2 unchanged sentences

If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties or other means, we may have to relinquish valuable rights to our setmelanotide program on terms that may not be favorable to us.

If we are unable to raise additional funds through equity, debt financings or other means, when needed, we may be

required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our setmelanotide program that we would otherwise prefer to develop and market ourselves.

If we are unable to raise additional funds through equity, debt financings or other means, when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our setmelanotide program that we would otherwise prefer to develop and market ourselves.

Contractual obligations

As of September 30, 2022, apart from additional contractual obligations under our RIFA as disclosed in Note 10, “Long-Term Obligations”, to the unaudited condensed consolidated financial statements included under Part I, Item 1 of this Quarterly Report on Form 10-Q, there were no other material changes to our principal contractual obligations and commitments as reported in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

Recent Accounting Pronouncements

For a discussion of pending and recently adopted accounting pronouncements, see Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

As of March 31, 2023, apart from additional contractual obligations under our acquisition of Xinvento as disclosed in Note 3, “Asset Acquisition”, to the unaudited condensed consolidated financial statements included under Part I, Item 1 of this Quarterly Report on Form 10-Q, there were no other material changes to our principal contractual obligations and commitments as reported in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Quantitative and Qualitative Disclosures About Market Risk

As of September 30, 2022, there were no material changes to our quantitative and qualitative disclosures about market risks as reported in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

As of March 31, 2023, there were no material changes to our quantitative and qualitative disclosures about market risks as reported in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis